Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 3

Infliximab in ulcerative colitis

Authors Levin A, Shibolet O

Published 12 September 2008 Volume 2008:2(3) Pages 379—388


Avi Levin, Oren Shibolet

Gastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, Israel

Abstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.

Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]